Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.50 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 6/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | PRKACA | P17612 | 1/20 | 0.47 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4053052 | 0.78 | MAP2K3 (0.56) | ASIC3MAP2K3MEN1KMT2ARAB9A | |
| SCHEMBL21857026 | 0.75 | MAP2K3 (0.58) | ASIC3MAP2K3MEN1KMT2ARAB9A | |
| SCHEMBL28247990 | 0.75 | ASIC3 (0.50) | ASIC3MAP2K3MEN1KMT2ARAB9A | |
| SCHEMBL1360818 | 0.75 | ALDH1A1 (0.59) | ASIC3MAP2K3MEN1KMT2ARAB9A | |
| SCHEMBL27807144 | 0.75 | ALDH1A1 (0.64) | ASIC3MAP2K3MEN1KMT2ARAB9A | |
| SCHEMBL14917463 | 0.73 | MEN1 (0.62) | ASIC3MAP2K3MEN1KMT2ARAB9A | |
| SCHEMBL20472126 | 0.72 | ADORA2A (0.48) | RAB9AMAPTCYP1A2SMN1; SMN2ADORA2A | |
| SCHEMBL8077324 | 0.72 | ASIC3 (0.47) | ASIC3MAP2K3MEN1KMT2ARAB9A | |
| SCHEMBL19009938 | 0.72 | TDO2 (0.45) | MEN1KMT2ARAB9ACYP1A2FTO | |
| SCHEMBL29106081 | 0.72 | FTO (0.62) | MAP2K3MEN1KMT2ARAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1814888-A1 | AZABENZOXAZOLES FOR THE TREATMENT OF CNS DISORDERS | Pfizer Products Incorporated (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20060173179-A1 | Azabenzoxazoles for the treatment of CNS disorders | PFIZER INC | 2006-08-03 | — | — | US | disclosed |
| WO-2006051394-A1 | AZABENZOXAZOLES FOR THE TREATMENT OF CNS DISORDERS | PFIZER PRODUCTS INC. (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173179-A1 | Azabenzoxazoles for the treatment of CNS disorders | CHRNA7, CHRNA5, CHRNA10 | ASIC3 2913/4885MAP2K3 2960/4885MEN1 3862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.